nanobiotix

What is NanoXray

The local control of cancer disease constitutes a fundamental step in anticancer treatment and is currently performed by surgery and radiotherapy. However, increased local control of cancer still represents a key challenge for improving patient outcomes. Radiotherapy treatment is currently limited by toxicity resulting from damage to healthy tissues and the difference between therapeutic effect and adverse events is referred to as the “therapeutic window“.

Nanobiotix is targeting this medical need: its NanoXray products have local mode of action and the potential to improve the effects of existing local therapy. NanoXray products work through and increase the therapeutic efficacy of an established and accepted physical mechanism of action that is used routinely in cancer treatment across the globe: radiotherapy. Radiotherapy is the most common tool for cancer treatment and is used in more than 5 million patients every year (representing 50 to 60% of total cancer patients).

NanoXray technology opens the therapeutic window by increasing the radiotherapy dose in the tumor without increasing damage to healthy tissue (see figure).

NanoXray’s therapeutic effects can be specifically controlled through targeted application of external ionizing radiation. These nanoparticles are to be activated in vivo by X-Rays regardless the linear accelerator used as source of ionizing radiation. Any equipment implemented in the clinic can be utilized for the activation of the NanoXray products.

The NanoXray technology is built around the concept that inert and inactive nanoparticles (typically 50 nm in diameter) can specifically absorb X-rays used in standard radiotherapy to deliver a higher efficient dose within the cancer cells. The nanoparticles have been specifically designed to address the huge unmet medical needs of radiotherapy.

The core NanoXray technology is designed around an inert and inactive compound that is not metabolized, meaning that are no potential side effects due to metabolites or products or off- activity. Just one administration is expected to be sufficient for the entire course of radiotherapy treatment.